Vericel

VCEL · NASDAQ

$40.58+$0.21 (+0.52%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $40.37

VCEL analyst rating

BuyConsensus of 3 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy3
Hold0
Underperform0
Sell0

12-month price target · 9 analysts

Average $61.78 (+52.2% upside)

Low: $55.55
Now: $40.58
High: $75.60

Upgrades and downgrades

The latest rating actions, newest first

VCEL analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Truist Securities	Oct 14, 2026	Maintains	Buy	$58.00 → $52.00	50%
TD Cowen	Jul 31, 2026	Maintains	Buy	$55.00 → $58.00	48%
Truist Securities	Jul 31, 2026	Maintains	Buy	$54.00 → $58.00	50%
HC Wainwright & Co.	Jul 31, 2026	Maintains	Buy	$70.00 → $72.00	43%
HC Wainwright & Co.	Jul 28, 2026	Maintains	Buy	$70.00	43%
Truist Securities	Jul 16, 2026	Maintains	Buy	$42.00 → $54.00	50%
HC Wainwright & Co.	May 8, 2026	Maintains	Buy	$64.00	43%
Truist Securities	Apr 15, 2026	Maintains	Buy	$48.00 → $42.00	50%
HC Wainwright & Co.	Feb 27, 2026	Maintains	Buy	$60.00 → $64.00	43%
Truist Securities	Dec 18, 2025	Maintains	Buy	$50.00 → $45.00	50%

The case for and against

Updated Feb 9, 2026

Bull case

Vericel Corporation is expected to experience significant revenue growth driven by its MACI product, with projections indicating a high-teens annual growth rate due to both an increase in volumes and annual average selling price (ASP) improvements. The company has demonstrated a robust growth trajectory, anticipating approximately 21.2% year-over-year growth in MACI revenues for fiscal year 2026, supported by a strong conversion rate of biopsies to MACI. Additionally, the fourth quarter is projected to show a notable 26% quarter-over-quarter revenue increase, indicating a solid performance outlook for the company.

Bear case

Vericel Corp's financial outlook is negatively impacted by a downward revision of projected MACI revenues for FY26 and FY27, indicating a decrease of approximately 200 basis points. The company faces several risks affecting its revenue, including slower adoption of MACI and MACI Arthro by physicians, sluggish sales in the burn care segment, and potential disruptions related to the expansion of its sales force. Moreover, any failure to meet top-line expectations in a quarter could result in the stock trading at historical low valuation levels, further reflecting the company's challenging position in the market.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.